Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply

Lancet Oncol. 2021 Aug;22(8):e343-e344. doi: 10.1016/S1470-2045(21)00419-8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Ipilimumab / adverse effects
  • Melanoma* / drug therapy
  • Nivolumab / adverse effects

Substances

  • Ipilimumab
  • Nivolumab